Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis ; volume:120 ; number:05 ; year:2020 ; pages:728-736
Thrombosis and haemostasis ; 120, Heft 05 (2020), 728-736
- Beteiligte Personen und Organisationen
-
Chowdary, Pratima
Fischer, Kathelijn
Collins, Peter W.
Cotterill, Amy
Konkle, Barbara A.
Blanchette, Victor
Pipe, Steven W.
Berntorp, Erik
Wolfsegger, Martin
Engl, Werner
Spotts, Gerald
- DOI
-
10.1055/s-0040-1709519
- URN
-
urn:nbn:de:101:1-2020080708523959752434
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chowdary, Pratima
- Fischer, Kathelijn
- Collins, Peter W.
- Cotterill, Amy
- Konkle, Barbara A.
- Blanchette, Victor
- Pipe, Steven W.
- Berntorp, Erik
- Wolfsegger, Martin
- Engl, Werner
- Spotts, Gerald
Ähnliche Objekte (12)
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia